Trials / Completed
CompletedNCT05984251
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Male and Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study will be to evaluate the safety and tolerability of single and multiple oral doses of CCX168, over a range of dose levels, in healthy male and female participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCX168 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2009-12-21
- Primary completion
- 2010-09-19
- Completion
- 2011-04-11
- First posted
- 2023-08-09
- Last updated
- 2023-08-09
Locations
1 site across 1 country: Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05984251. Inclusion in this directory is not an endorsement.